The TSX Venture Exchange has accepted for filing documentation with respect to the arm's-length acquisition of all outstanding shares of Lipdro Therapeutics Inc., pursuant to a share purchase agreement dated June 30, 2025, between Arch Biopartners Inc. and an arm's-length vendor.

Pursuant to the terms of the agreement and as consideration for the acquisition, the company issued 250,000 common shares in the capital of the company at a deemed price of $1.85 per share to the vendor on closing of the acquisition. Additionally, the company has granted the vendor a royalty based on net sales of future products derived from the acquired assets.

For further details, please refer to the company's news release dated Sept. 17, 2025.